Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Retained Earnings (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Retained Earnings data on record, last reported at -$1.1 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 99.72% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$1.1 million, up 99.72%, while the annual FY2024 figure was -$397.0 million, 40955.84% down from the prior year.
  • Retained Earnings reached -$1.1 million in Q3 2025 per CRVS's latest filing, up from -$389.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$434000.0 in Q1 2023 and bottomed at -$397.0 million in Q4 2024.
  • Average Retained Earnings over 4 years is -$244.9 million, with a median of -$307.7 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.84% in 2023, then plummeted 78333.18% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$307.7 million in 2022, then soared by 99.69% to -$967000.0 in 2023, then plummeted by 40955.84% to -$397.0 million in 2024, then surged by 99.73% to -$1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.1 million in Q3 2025, -$389.8 million in Q2 2025, and -$1.3 million in Q1 2025.